These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34281885)

  • 1. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
    Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
    Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
    Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
    PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
    Gordian-Arroyo AM; Zynger DL; Tozbikian GH
    Am J Clin Pathol; 2019 Jun; 152(1):17-26. PubMed ID: 30958889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
    Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
    McLemore LE; Albarracin CT; Gruschkus SK; Bassett RL; Wu Y; Dhamne S; Yim I; Lin K; Bedrosian I; Sneige N; Chen H
    Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines.
    Qian XL; Wen HY; Yang YL; Gu F; Guo XJ; Liu FF; Zhang L; Zhang XM; Fu L
    Breast Cancer Res Treat; 2016 Aug; 159(1):31-9. PubMed ID: 27455837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.
    Pasricha S; Gupta G; Garg R; Sharma A; Gandhi JS; Durga G; Kamboj M; Grover S; Mehta A
    Breast J; 2018 Jul; 24(4):468-472. PubMed ID: 29251392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
    Zhang X; Bleiweiss I; Jaffer S; Nayak A
    Clin Breast Cancer; 2017 Oct; 17(6):486-492. PubMed ID: 28433541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.